NEW YORK--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE: FRX), an international manufacturer and marketer of pharmaceutical products, today announced that it will host a meeting on Wednesday, June 20, 2012 to review its late-stage product development pipeline and commercialization strategy. The meeting will feature therapeutic area presentations by senior leadership from the Forest Research Institute, Inc., the Company’s research and development arm, and product commercialization strategy by senior corporate executives, with emphasis placed on the Company’s late-stage product opportunities and new product launches.
The meeting will be webcast live on the investor relations section of the Forest Laboratories website at www.frx.com. A link to access the webcast will become available on the Forest website later in May.
About Forest Laboratories
Forest Laboratories’ (NYSE: FRX) longstanding global partnerships and track record developing and marketing pharmaceutical products in the United States have yielded its well-established central nervous system and cardiovascular franchises and innovations in anti-infective and respiratory medicine. The Company’s pipeline, the most robust in its history, includes product candidates in all stages of development across a wide range of therapeutic areas. The Company is headquartered in New York, NY. To learn more, visit www.FRX.com.
Except for the historical information contained herein, this release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, the acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in Forest Laboratories’ Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and any subsequent SEC filings.